Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

Abstract:
Carigent Therapeutics, Inc., announced today that the National Cancer Institute of the National Institutes of Health has awarded Carigent a one-year, $153,000 Phase I Small Business Innovation Research (SBIR) grant to advance preclinical development of an innovative, long-circulating nanoparticle therapeutic that targets the specific molecular lesions in non-Hodgkin's lymphoma (NHL) patients.

Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

New Haven, CT | Posted on January 16th, 2008

Carigent's novel therapeutic approach is based on the company's proprietary technology for engineering biodegradable nanoparticles with exceptionally high-density surface modifications. The platform enables Carigent to design customized, multifunctional nanoscale carriers with the unique combined capability of:
Tethering multiple "functional groups" such as targeting ligands, diagnostic imaging agents, and polyethylene glycol (PEG) to the nanoparticle surface at previously unattainable densities, and Encapsulating single or combined therapeutic and/or diagnostic agents inside the nanoparticle for sustained, controlled release directly into targeted (i.e., diseased) tissues and cells.

"Non-Hodgkin's lymphoma has one of the fastest-growing incidence rates among cancers and is now the sixth most common cancer in the U.S.," said Seth Feuerstein, MD, JD, President and a co-founder of Carigent. "As we accelerate development of Carigent's engineered nanoparticle therapeutics to address unmet needs in cancer treatment, we are grateful for this financial support from the National Cancer Institute and the additional validation it provides Carigent's versatile nanoparticle delivery technology. The ability to modify particles for targeting as well as increased circulation time is what makes this an exciting project for the field."

####

About Carigent Therapeutics, Inc.
Carigent Therapeutics, Inc. is a biotechnology company developing and commercializing safer and more effective therapeutic and diagnostic products based on the companys platform technology: Nanoparticles that enable delivery and controlled release of therapeutic and diagnostic agents into specific locations within the body and tissues. The companys products and services are based on novel nanotechnology developed at Yale University that provides the unique capability of tethering agents for targeting, imaging, and increased circulation time at unprecedented densities to the surface of biodegradable polymer nanoparticles, resulting in drugs that bind to their targets more effectively, are delivered at a higher concentration to the desired location, and/or remain in the bloodstream longer than other nanotechnology-based drugs. The Carigent technology is broadly applicable across a wide variety of disease states and supports multiple types of targeting strategies and carrier designs for existing drugs as well as new drugs in development. Carigents initial product development programs are focused on cancer therapeutics. In parallel, Carigent provides access to its nanoparticle drug delivery technology through collaborations and partnerships with pharmaceutical, biotechnology, and diagnostics companies. Carigent was established in 2007 and is based in New Haven, Connecticut.

For more information, please click here

Contacts:
Mary Moynihan
M2Friend Biocommunications
(802) 951-9600

Copyright © Carigent Therapeutics, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

INVECAS to Enable ASIC Designs for Tomorrows Intelligent Systems on GLOBALFOUNDRIES' FDX Technology: INVECAS to Collaborate with GLOBALFOUNDRIES to Provide IP and End-to-End ASIC Design Services on 22FDX and 12FDX Technologies September 30th, 2016

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Innovation in Nanotechnology is Focus of Symposium: Annual event brings international experts to Northwestern Oct. 6 September 29th, 2016

Govt.-Legislation/Regulation/Funding/Policy

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Crystalline Fault Lines Provide Pathway for Solar Cell Current: New tomographic AFM imaging technique reveals that microstructural defects, generally thought to be detrimental, actually improve conductivity in cadmium telluride solar cells September 26th, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

PHENOMEN is a FET-Open Research Project aiming to lay the foundations a new information technology September 19th, 2016

Nanomedicine

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Nanosensors could help determine tumors ability to remodel tissue: Measuring enzyme levels could help doctors select appropriate treatments September 29th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Announcements

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

INVECAS to Enable ASIC Designs for Tomorrows Intelligent Systems on GLOBALFOUNDRIES' FDX Technology: INVECAS to Collaborate with GLOBALFOUNDRIES to Provide IP and End-to-End ASIC Design Services on 22FDX and 12FDX Technologies September 30th, 2016

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Innovation in Nanotechnology is Focus of Symposium: Annual event brings international experts to Northwestern Oct. 6 September 29th, 2016

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Semiconducting inorganic double helix: New flexible semiconductor for electronics, solar technology and photo catalysis September 15th, 2016

Bringing graphene speakers to the mobile market (video) September 12th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic